Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants that differentiate its shingles vaccine candidate and for use by other developers through licensing partnerships.
Our vaccine candidates in shingles and pertussis aim to provide a better experience for the recipient and the same protection against disease. The next generation semi-synthetic saponin adjuvants are used in our vaccines and with partner vaccine candidates in infectious disease, immuno-oncology, neurobiology, substance abuse, and allergy. Our first adjuvant, TQL-1055, has demonstrated vaccine immunogenicity and favorable tolerability in a clinical trial.
Keep up with the latest news about Adjuvance Technologies, including news releases, development updates, and more.
Patent Covers TQL-1055 Adjuvant for Multiple Uses, Including Shingles Vaccine Protects the Foundation of the Company’s Proprietary Adjuvant Technology Lincoln, NE, January 7, 2022 – Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company...